NCT07064889View on ClinicalTrials.gov

The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

December 30, 2027

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Dexamethasone

Dexamethasone, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

DRUG

Upadacitinib

Upadacitinib 15mg qd for 12 weeks

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Beijing Aerospace General Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Beijing Tongren Hospital

OTHER

lead

Peking University People's Hospital

OTHER